Related references
Note: Only part of the references are listed.Clinical and Translational Applications of Serological and Histopathological Biomarkers in Metastatic Breast Cancer: A Comprehensive Review
Leonel Pekarek et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2023)
Clinical utility of liquid biopsy in breast cancer: A systematic review
Galo Duque et al.
CLINICAL GENETICS (2022)
Breast cancer-specific mortality in early breast cancer as defined by high-risk clinical and pathologic characteristics
David R. Nelson et al.
PLOS ONE (2022)
Global patterns of breast cancer incidence and mortality: A population-based cancer registry data analysis from 2000 to 2020
Shaoyuan Lei et al.
CANCER COMMUNICATIONS (2021)
Development of a Nomogram to Predict the Recurrence Score of 21-Gene Prediction Assay in Hormone Receptor Positive Early Breast Cancer
Shin Hye Yoo et al.
CLINICAL BREAST CANCER (2020)
Androgen Receptor in Breast Cancer-Clinical and Preclinical Research Insights
Aristomenis Anestis et al.
MOLECULES (2020)
Oncotype DX Breast Recurrence Score(R): A Review of its Use in Early-Stage Breast Cancer
Yahiya Y. Syed
MOLECULAR DIAGNOSIS & THERAPY (2020)
Androgen Receptor in Breast Cancer: From Bench to Bedside
Mengyao Chen et al.
FRONTIERS IN ENDOCRINOLOGY (2020)
Breast Cancer Statistics in Korea in 2017: Data from a Breast Cancer Registry
Sang Yull Kang et al.
JOURNAL OF BREAST CANCER (2020)
Prognostic models for breast cancer: a systematic review
Minh Tung Phung et al.
BMC CANCER (2019)
Association of p53 expression with poor prognosis in patients with triple-negative breast invasive ductal carcinoma
Jing-ping Li et al.
MEDICINE (2019)
Clinical and Genomic Risk to Guide the Use of Adjuvant Therapy for Breast Cancer
Joseph A. Sparano et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
Nomogram update based on TAILORx clinical trial results - Oncotype DX breast cancer recurrence score can be predicted using clinicopathologic data
Amila Orucevic et al.
BREAST (2019)
Use of Biomarkers to Guide Decisions on Adjuvant Systemic Therapy for Women With Early-Stage Invasive Breast Cancer: ASCO Clinical Practice Guideline Update-Integration of Results From TAILORx
Fabrice Andre et al.
JOURNAL OF CLINICAL ONCOLOGY (2019)
A Nomogram for Predicting the Oncotype DX Recurrence Score in Women with T1-3N0-1miM0 Hormone Receptor-Positive, Human Epidermal Growth Factor 2 (HER2)-Negative Breast Cancer
Sae Byul Lee et al.
CANCER RESEARCH AND TREATMENT (2019)
Verification of a Western Nomogram for Predicting Oncotype DX™ Recurrence Scores in Korean Patients with Breast Cancer
Jae-Myung Kim et al.
JOURNAL OF BREAST CANCER (2018)
Adjuvant Chemotherapy Guided by a 21-Gene Expression Assay in Breast Cancer
J. A. Sparano et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Luminal-like HER2-negative stage IA breast cancer: a multicenter retrospective study on long-term outcome with propensity score analysis
Carmine De Angelis et al.
ONCOTARGET (2017)
Oncotype DX breast cancer recurrence score can be predicted with a novel nomogram using clinicopathologic data
Amila Orucevic et al.
BREAST CANCER RESEARCH AND TREATMENT (2017)
Utilization and impact of 21-gene recurrence score assay for breast cancer in clinical practice across the United States: lessons learned from the 2010 to 2012 National Cancer Data Base analysis
Amila Orucevic et al.
BREAST CANCER RESEARCH AND TREATMENT (2016)
Pooled analysis of prospective European studies assessing the impact of using the 21-gene Recurrence Score assay on clinical decision making in women with oestrogen receptor-positive, human epidermal growth factor receptor 2enegative early-stage breast cancer
Joan Albanell et al.
EUROPEAN JOURNAL OF CANCER (2016)
BCL2 as a Subtype-Specific Prognostic Marker for Breast Cancer
Yong Hwa Eom et al.
JOURNAL OF BREAST CANCER (2016)
Expression of Androgen Receptor in Estrogen Receptor-positive Breast Cancer
Anil Agrawal et al.
APPLIED IMMUNOHISTOCHEMISTRY & MOLECULAR MORPHOLOGY (2016)
A Validated Model for Identifying Patients Unlikely to Benefit From the 21-Gene Recurrence Score Assay
Michele M. Gage et al.
CLINICAL BREAST CANCER (2015)
Prospective Validation of a 21-Gene Expression Assay in Breast Cancer
J. A. Sparano et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Effectiveness of an Adjuvant Chemotherapy Regimen for Early-Stage Breast Cancer
Takeo Fujii et al.
JAMA ONCOLOGY (2015)
The Performance of the Nottingham Prognosis Index and the Adjuvant Online Decision Making Tool for Prognosis in Early-stage Breast Cancer Patients
Mehri Rejali et al.
INTERNATIONAL JOURNAL OF PREVENTIVE MEDICINE (2015)
Prediction of Oncotype DX and TAILORx risk categories using histopathological and immunohistochemical markers by classification and regression tree (CART) analysis
Helen Ingoldsby et al.
BREAST (2013)
Routine Histopathologic Characteristics Can Predict Oncotype DX™ Recurrence Score in Subsets of Breast Cancer Patients
Malcolm D. Mattes et al.
CANCER INVESTIGATION (2013)
Integrating comparative effectiveness design elements and endpoints into a phase III, randomized clinical trial (SWOG S1007) evaluating oncotypeDX-guided management for women with breast cancer involving lymph nodes
Scott D. Ramsey et al.
CONTEMPORARY CLINICAL TRIALS (2013)
Cost-effectiveness of the 21-gene recurrence score assay in the context of multifactorial decision making to guide chemotherapy for early-stage breast cancer
Shelby D. Reed et al.
GENETICS IN MEDICINE (2013)
The impact of p53 in predicting clinical outcome of breast cancer patients with visceral metastasis
P. Yang et al.
SCIENTIFIC REPORTS (2013)
Routine pathologic parameters can predict Oncotype DXTM recurrence scores in subsets of ER positive patients: who does not always need testing?
K. H. Allison et al.
BREAST CANCER RESEARCH AND TREATMENT (2012)
Comparisons between different polychemotherapy regimens for early breast cancer: meta-analyses of long-term outcome among 100 000 women in 123 randomised trials
K. Albain et al.
LANCET (2012)
The Oncotype DX Recurrence Score Is Correlated With a Composite Index Including Routinely Reported Pathobiologic Features
Joseph Geradts et al.
CANCER INVESTIGATION (2010)
Tumor-Associated Lymphocytes As an Independent Predictor of Response to Neoadjuvant Chemotherapy in Breast Cancer
Carsten Denkert et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
The Impact of Primary Tumor Size, Lymph Node Status, and Other Prognostic Factors on the Risk of Cancer Death
L. Leon Chen et al.
CANCER (2009)
Efficacy of adjuvant chemotherapy according to hormone receptor status in young patients with breast cancer: a pooled analysis
Jos A. van der Hage et al.
BREAST CANCER RESEARCH (2007)
TAILORx: Trial assigning individualized options for treatment (Rx)
Joseph A. Sparano
CLINICAL BREAST CANCER (2006)
Gene expression and benefit of chemotherapy in women with node-negative, estrogen receptor-positive breast cancer
Soonmyung Paik et al.
JOURNAL OF CLINICAL ONCOLOGY (2006)
A population-based study of tumor gene expression and risk of breast cancer death among lymph node-negative patients
Laurel A. Habel et al.
BREAST CANCER RESEARCH (2006)
A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer
S Paik et al.
NEW ENGLAND JOURNAL OF MEDICINE (2004)
Share Paper
